The value of plasma pro-gastrin-releasing peptide, cytokeratin 19-fragments and carcinoembryonic antigen in patients with lung cancer
10.3760/cma.j.issn.1003-9279.2011.05.020
- VernacularTitle:血浆胃泌素释放肽前体,细胞角蛋白19和癌胚抗原对各型肺肿瘤的诊断价值
- Author:
Yong-Jian CHEN
1
;
Wei-Dong JIN
;
Guang-Yu YANG
;
Yong-Lie ZHOU
;
Mei ZHU
Author Information
1. 浙江省人民医院
- Keywords:
Lung neoplasms/diagnosis;
Carcimcoma,small cell;
Grastrin-releasing peptide
- From:
Chinese Journal of Experimental and Clinical Virology
2011;25(5):381-383
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the value of plasma ProGRP,CYFRA 21-1 and CEA in patiens with lung cancer.Methods The levels of plasma ProGRP,CYFRA 21-1 and CEA were detected in 85 healthy control,49 benign lung diseases and 143 lung neoplasms.The levels of ProGRP in the patients with SCLC was monitored.Results The level of plasma ProGRP in SCLC ( M 179.1 ng/ml) was significantly higher than adenocarcinoma ( M 35.3 ng/ml),squamous-cell carcinoma ( M 33.3 ng/ml),healthy control (M 35.6 ng/m)and benign lung diseases (M 33.3ng/m ),P ＜ 0.001.The sensitivity and specificity for diagnosing SCLC by ProGRP were 60.6％ and 95.0％ respectively.In the effective treatment group,ProGRP reduced 45.9％,in the progression group,ProGRP increased 103.1％,P ＜ 0.05.The level of CEA in the metastatic adenocarcinoma (M 10.22 ng/ml ) was significantly higher than non-metastatic adenocarcinoma ( M 3.85ng/ml) and squamous cell carcinoma ( M 2.56 ng/ml) ( P ＜ 0.01 ).Conclusion The plasma ProGRP is a good indicator for diagnosing and evaluating cure effect in SCLC; the high expression of CEA is related to the metastatic adenocarcinoma.
